title: Reappraisal of bronchial arterial infusion therapy for advanced lung cancer.
abstract: As preoperative adjuvant therapy for advanced lung cancer, bronchial arterial infusion (BAI) of a chemotherapeutic agent was administered to patients with stage IIIa and IIIb hilar lung cancer. The infusion modality was changed for each term, from a single drug infusion, to a two drug infusion and then a three drug infusion, and the combination of infused drugs was selected in accordance with cell types. A significant radiographic shrinkage was observed after BAI therapy by the single, two and three drug infusions, being noted as 40.7 per cent, 61.8 per cent and 83.9 per cent, respectively. The effect on squamous cell carcinoma was more prominent than on other cell types. Upon microscopic examination of the resected specimens, significant histo-pathological effects were observed in 57.7 per cent of the patients who received single or two drug infusions, while the rate increased to as high as 92.2 per cent in the patients who received the three drug infusion. The histological effects of BAI therapy were also most marked in squamous cell carcinoma. It is of special interest that 5 of the 10 patients who received the three drug infusion of Carboquone (CQ) + Mitomycin C (MMC) + Nimustine-HCL (ACNU) for squamous cell carcinoma, showed complete disappearance of viable cancer cells at the tumor site; something which was never observed after the single and two drug infusions. It was therefore concluded that BAI therapy for advanced lung cancer should be reappraised through the modification of infusion methods.
authors.affiliation: Department of Surgery, Kanazawa University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: J
authors.initials: J
authors.lastname: Shimizu
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.forename: M
authors.initials: M
authors.lastname: Tsubota
authors.forename: T
authors.initials: T
authors.lastname: Iwa
authors.forename: M
authors.initials: M
authors.lastname: Kitagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Mizukami
authors.forename: A
authors.initials: A
authors.lastname: Nonomura
authors.forename: F
authors.initials: F
authors.lastname: Matsubara
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D002225:Carbazilquinone / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007261:Infusions, Intra-Arterial; D008168:Lung / Q000098:blood supply; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D015376:Nimustine / Q000008:administration & dosage; D011859:Radiography
chemical_list: D000277:Adjuvants, Pharmaceutic; D008937:Mitomycins; D015376:Nimustine; D002225:Carbazilquinone; D016685:Mitomycin